Referencias bibliográficas
1. Ficha técnica Paclitaxel (Taxol®).
2. Bagnall A-M, Forbes C, Lewis R, Golder S, Kleijnen J. An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast cancer. The National Institute for Clinical Excellence (NHS Centre for Reviews and Dissemination). University of York, April 2001.
3. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94:66-72.
4. Vervolet D, Durham S. Adverse reactions to drugs. BMJ 1998; 316:1511-1514
5. UpToDate. Base de Datos. Infusion reactions to systemic chemotherapy; October 2009.
6. Michaud LB. Methods for preventing reactions secondary to Cremophor EL. Ann Pharmacother 1997; 31:1402-4.
7. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008; 122 (3):574-80.
8. Espinosa Aunión, R, González Sánchez, L.A., Oruézabal Moreno, M.J., Barberá Farré, J.R. Desensibilización a paclitaxel en paciente con reacción alérgica moderada-severa. Oncología 2007; vol. 30(4): 41-44.
9. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005; 96: 824-9.
10. Fishman A, Gold T, Goldberg A, Confino-Cohen R, Beyth Y, Menczer J, et al. Effective desensitization protocol to paclitaxel following hypersensitivity reaction. Int J Gynecol Cancer. 1999; 9:156-9.
11. Gligorov J, Lotz J-P. Preclinical Pharmacology of the taxanes: implications of the differences. The oncologist. 2004; 9 (Supl 2): 3-8.
12. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological efects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003; 42 (7): 665-85.
13. Fader AN, Rose PG. Abraxane for the Treatment of Gynecologic Cancer Patiens with Severe Hypersensitivity Reactions to Paclitaxel. Int J Gynecol Cancer. 2009; 19:1281-3.
14. J. Lokich J, Anderson N. Paclitaxel hypersensitivity reactions: A role for docetaxel subsitution. The Cancer Center of Boston. Annals of Oncology. 1998; 9: 573-4.
15. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11(7):565-8.
16. Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, Disilvestro P, et al. Cross-sensitivity between paclitaxel and docetaxel in a women’s cancers program. Gynecol Oncol. 2006; 100 (1): 149-51